

Merus Labs International Inc.
Form 6-K
March 07, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

**PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **March 2016**

Commission File No. **000-30082**

MERUS LABS INTERNATIONAL INC.

(Translation of registrant's name into English)

100 Wellington St. West, Suite 2110 P.O. Box 151

Toronto, ON M5K 1H1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [☐] **Form 40-F [X]**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1) [☐]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7) [☐]

SUBMITTED HEREWITH

Exhibits

- 99.1 News Release Dated March 7, 2016 - Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from Sanofi

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 7, 2016

MERUS LABS INTERNATIONAL INC.

/s/ Andrew Patient

Andrew Patient
Chief Financial Officer